<DOC>
	<DOCNO>NCT00117468</DOCNO>
	<brief_summary>This single-center , open-label , randomize , active-controlled study compare DR-2011 progesterone vaginal gel luteal phase replacement .</brief_summary>
	<brief_title>Comparison DR-2011 Progesterone Vaginal Gel Luteal Phase Replacement</brief_title>
	<detailed_description>This 2-arm , single-center , open-label , randomize , active-controlled study compare safety efficacy luteal phase replacement DR-2011 progesterone vaginal gel 18-day treatment period . Patients also require use estrogen patch course study . The overall study duration patient approximately 1Â½ month . Luteal phase replacement monitor endometrial biopsy Cycle Day 25 26 . In addition , serum hormonal level measure screening designate time Cycle Day 14 31 .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Not pregnant Clinically medicallyinduced nonfunctioning surgically remove ovary Clinical investigator believe patient would eligible oocyte donation Any contraindication progesterone estrogen therapy Undiagnosed vaginal bleeding History uterine fibroid condition could adversely affect pregnancy success Hysterectomy Any contraindication vaginal drug delivery system</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>luteal phase replacement</keyword>
	<keyword>oocyte donation</keyword>
	<keyword>infertility</keyword>
	<keyword>progesterone</keyword>
</DOC>